Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency
June 22 2021 - 7:00AM
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field
of cellular metabolism developing and delivering innovative
treatments for genetically defined diseases, today announced the
launch of myAgios® patient support services for people living with
pyruvate kinase (PK) deficiency and their caregivers. After
enrolling in the program, patients and caregivers will be connected
with a dedicated Patient Support Manager (PSM) with a clinical
background to provide tailored support, educational resources and
opportunities to connect with other patients and caregivers in the
community.
“Pyruvate kinase deficiency is a lifelong hemolytic anemia with
no disease-modifying treatments currently available to patients.
Because it’s a rare disease, individuals who receive a diagnosis
may be looking for a place to connect and learn more about their
condition,” said Jackie Fouse, Ph.D., chief executive officer of
Agios. “That’s why we’re thrilled to launch the myAgios program for
this community. Patients and caregivers will be connected with
someone who is knowledgeable, personable and empathetic as they
navigate together the unique set of challenges that comes with a
pyruvate kinase deficiency diagnosis. Ultimately, we hope this
program will help patients and their caregivers communicate more
effectively with healthcare providers and feel empowered to better
manage their care or the care of their loved one.”
Agios developed the myAgios patient support program in response
to insights from patients, caregivers, advocates and physicians
surrounding the challenges and needs in the PK deficiency
community, including variations in care, age-related impact,
educational resources available to healthcare providers and overall
impact on mental health. Patients and caregivers interested in
obtaining more detailed content about PK deficiency can enroll in
the patient support program at www.myagios.com/patient/pkd-enroll.
Agios will also host a virtual webinar series on the program,
featuring subject matter experts in the PK deficiency community who
will share their perspectives. The series, titled Know PK
Deficiency, launches at 7 p.m. ET on Wednesday, June 23. More
information and registration details are available at
www.knowpkdeficiency.com/patient-programs.
About PK DeficiencyPyruvate kinase (PK)
deficiency is a rare, inherited disease that presents as chronic
hemolytic anemia, which is the accelerated destruction of red blood
cells. The inherited mutations in PKR genes cause a deficit in
energy within the red blood cell, as evidenced by lower PK enzyme
activity, a decline in adenosine triphosphate (ATP) levels and a
build-up of upstream metabolites, including 2,3-DPG
(2,3-diphosphoglycerate).
PK deficiency is associated with serious complications,
including gallstones, pulmonary hypertension, extramedullary
hematopoiesis, osteoporosis and iron overload and its sequelae,
which can occur regardless of the degree of anemia or transfusion
burden. PK deficiency can also cause quality of life problems,
including challenges with work and school activities, social life
and emotional health. Current management strategies for PK
deficiency, including red blood cell transfusions and splenectomy,
are associated with both short- and long-term risks. There are no
currently approved therapies for PK deficiency. For more
information, please visit www.knowpkdeficiency.com.
Agios, in partnership with PerkinElmer Genomics, launched the
Anemia ID program to offer no-cost genetic testing to eligible
patients in the U.S with suspected hereditary anemias,
including PK deficiency. The program was created in response to
feedback from patients, advocates and physicians about the need for
improved diagnosis to inform disease management decisions. To learn
more, please visit www.AnemiaID.com.
About AgiosAgios is focused on discovering and
developing novel investigational medicines to treat genetically
defined diseases through scientific leadership in the field of
cellular metabolism. The company’s most advanced drug candidate is
a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that
is currently being evaluated for the treatment of three distinct
hemolytic anemias. In addition to its active late-stage clinical
pipeline, Agios has multiple novel, investigational therapies in
clinical and preclinical development. For more information, please
visit the company’s website at www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the potential benefits of the myAgiosTM patient
support program; and the benefit of Agios’ strategic plans and
focus. The words "expects," "anticipates," "believes," "intends,"
"estimates," "plans," "will," "outlook," "goal", "potential" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from Agios' current
expectations and beliefs. Management's expectations and, therefore,
any forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
important factors, including: risks and uncertainties related to
the impact of the COVID-19 pandemic to Agios’ business, operations,
strategy, goals and anticipated milestones, including its ongoing
and planned research activities, ability to conduct ongoing and
planned clinical trials, clinical supply of current or future drug
candidates, commercial supply of future approved products, and
launching, marketing and selling future approved products; the
results of Agios’ clinical trials and preclinical studies,
including subsequent analysis of existing data and new data
received from ongoing and future studies; the content and timing of
decisions made by regulatory authorities, investigational review
boards at clinical trial sites and publication review bodies;
Agios' ability to obtain and maintain requisite regulatory
approvals and to enroll patients and conduct its current and future
clinical trials; unplanned cash requirements and expenditures;
competitive factors; Agios' ability to obtain, maintain and enforce
patent and other intellectual property protection for any product
candidates it is developing; Agios' ability to maintain key
collaborations; and general economic, market and global health
conditions. These and other risks are described in greater detail
under the caption "Risk Factors" included in Agios’ public filings
with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Contacts
Investors: 1AB Steve
Klasssteve@1abmedia.com
Media: 1AB Josie Butlerjosie@1abmedia.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024